BioNTech’s (BNTX) “Buy” Rating Reaffirmed at HC Wainwright

BioNTech (NASDAQ:BNTXGet Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a report released on Monday, Benzinga reports. They currently have a $113.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 12.62% from the company’s current price.

Several other research firms also recently weighed in on BNTX. The Goldman Sachs Group reduced their target price on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 28th. TD Cowen lifted their target price on shares of BioNTech from $95.00 to $98.00 and gave the stock a “hold” rating in a research note on Tuesday, May 7th. Evercore ISI assumed coverage on shares of BioNTech in a research note on Tuesday, May 14th. They issued an “inline” rating and a $100.00 target price for the company. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research note on Thursday, March 21st. Finally, BMO Capital Markets reduced their price objective on shares of BioNTech from $123.00 to $122.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $111.70.

Check Out Our Latest Research Report on BioNTech

BioNTech Trading Down 1.4 %

Shares of BNTX stock opened at $100.34 on Monday. BioNTech has a 52-week low of $85.21 and a 52-week high of $125.83. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.16 and a current ratio of 11.38. The company has a 50-day simple moving average of $92.27 and a two-hundred day simple moving average of $95.81. The company has a market capitalization of $23.85 billion, a price-to-earnings ratio of 200.68 and a beta of 0.27.

BioNTech (NASDAQ:BNTXGet Free Report) last issued its quarterly earnings data on Monday, May 6th. The company reported ($1.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.60). The firm had revenue of $203.69 million during the quarter, compared to the consensus estimate of $589.96 million. BioNTech had a return on equity of 0.55% and a net margin of 4.01%. Research analysts anticipate that BioNTech will post -2.11 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of BNTX. Harding Loevner LP purchased a new position in BioNTech in the 4th quarter worth approximately $410,984,000. Baillie Gifford & Co. lifted its holdings in shares of BioNTech by 15.5% in the 3rd quarter. Baillie Gifford & Co. now owns 8,602,839 shares of the company’s stock worth $934,612,000 after acquiring an additional 1,152,541 shares during the last quarter. Clearbridge Investments LLC lifted its holdings in shares of BioNTech by 41.6% in the 3rd quarter. Clearbridge Investments LLC now owns 484,126 shares of the company’s stock worth $52,595,000 after acquiring an additional 142,344 shares during the last quarter. Primecap Management Co. CA lifted its holdings in shares of BioNTech by 2.8% in the 4th quarter. Primecap Management Co. CA now owns 4,763,453 shares of the company’s stock worth $502,735,000 after acquiring an additional 131,490 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in shares of BioNTech by 43.1% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 425,071 shares of the company’s stock worth $44,610,000 after acquiring an additional 127,951 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

(Get Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Articles

Analyst Recommendations for BioNTech (NASDAQ:BNTX)

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.